We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+22.99%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$758M
AUM Growth
+$569M
Cap. Flow
+$474M
Cap. Flow %
62.53%
Top 10 Hldgs %
80.56%
Holding
85
New
22
Increased
12
Reduced
26
Closed
20

Top Buys

Rank Stock Value
1
BCAB icon
BioAtla
BCAB
+$106M
2
DMRA
Damora Therapeutics, Inc. Ordinary Shares
DMRA
+$22.5M
3
NVTA
Invitae Corporation
NVTA
+$11.7M
4
EXEL icon
Exelixis
EXEL
+$8.18M
5
CCCC icon
C4 Therapeutics
CCCC
+$7.79M

Top Sells

Rank Stock Value
1
OSUR icon
OraSure Technologies
OSUR
+$7.61M
2
QDEL icon
QuidelOrtho
QDEL
+$6.75M
3
IMMU
Immunomedics Inc
IMMU
+$6.49M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$6.48M
5
INBX
Inhibrx, Inc. Common Stock
INBX
+$5.13M

Sector Composition

Rank Sector Weight
1 Healthcare 43.51%
2 Consumer Staples 0.62%
3 Real Estate 0.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.2B
$398M 52.48%
+2,825,000
New +$362M
BCAB icon
2
BioAtla
BCAB
$5.59M
$108M 14.27%
+63,587
New +$106M
EPIX
3
DELISTED
ESSA Pharma
EPIX
$28.3M 3.74%
2,375,681
+548,701
+30% +$3.86M
DMRA
4
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.77B
$18.9M 2.5%
+60,506
New +$22.5M
ISEE
5
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$11M 1.46%
1,597,279
-88,600
-5% -$567K
NVTA
6
DELISTED
Invitae Corporation
NVTA
$10.2M 1.35%
+244,760
New +$11.7M
LNTH icon
7
Lantheus
LNTH
$6.82B
$10M 1.32%
742,085
+232,541
+46% +$3.04M
CCCC icon
8
C4 Therapeutics
CCCC
$376M
$8.9M 1.17%
+268,548
New +$7.79M
XENE icon
9
Xenon Pharmaceuticals
XENE
$6.32B
$8.58M 1.13%
558,117
+57,853
+12% +$677K
EXEL icon
10
Exelixis
EXEL
$13.9B
$7.84M 1.04%
+390,847
New +$8.18M
NTRA icon
11
Natera
NTRA
$37.5B
$7.38M 0.97%
74,189
-26,900
-27% -$2.25M
VCEL icon
12
Vericel Corp
VCEL
$2.3B
$7.3M 0.96%
236,589
-116,417
-33% -$2.77M
INBX
13
DELISTED
Inhibrx, Inc. Common Stock
INBX
$7.05M 0.93%
213,807
-192,693
-47% -$5.13M
IRMD icon
14
iRadimed
IRMD
$1.21B
$6.93M 0.91%
303,998
+105,259
+53% +$2.43M
TCRR
15
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$6.18M 0.82%
199,867
-82,174
-29% -$2.08M
DRIO icon
16
DarioHealth
DRIO
$57M
$5.74M 0.76%
+20,080
New +$5.18M
MRSN
17
DELISTED
Mersana Therapeutics
MRSN
$5.5M 0.73%
8,274
-7,448
-47% -$4.14M
LYRA
18
DELISTED
LYRA THERAPEUTICS INC
LYRA
$5.2M 0.69%
9,123
+6,910
+312% +$3.89M
SPRY icon
19
ARS Pharmaceuticals
SPRY
$590M
$5M 0.66%
+107,826
New +$3.6M
SKIN icon
20
SkinHealth Systems
SKIN
$94.9M
$4.71M 0.62%
+416,551
New +$4.48M
NVCR icon
21
NovoCure
NVCR
$2.04B
$4.33M 0.57%
24,999
-27,378
-52% -$3.75M
HIMS icon
22
Hims & Hers Health
HIMS
$6.5B
$4.11M 0.54%
+281,565
New +$3.13M
SRDX
23
DELISTED
Surmodics
SRDX
$4.05M 0.53%
92,975
+15,692
+20% +$618K
MSON
24
DELISTED
Misonix Inc
MSON
$3.77M 0.5%
301,333
+51,080
+20% +$645K
AZN icon
25
AstraZeneca
AZN
$263B
$3.21M 0.42%
32,142
+27,540
+598% +$2.92M
1
2 3 4

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
JC
JB Capital Wethersfield, Connecticut $2.48B AUM 22.31% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
BW
BIP Wealth Atlanta, Georgia $2.46B AUM 14.38% 1-Year Est. Return
BL
Balentine LLC Atlanta, Georgia $2.48B AUM 17.44% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return

Soleus Capital Management's Q4 2020 Portfolio in Review

As of Q4 2020, Soleus Capital Management held 85 positions worth $758M, up 302% from $189M the previous quarter. Its ten largest holdings account for 81% of the portfolio.

Soleus Capital Management deployed $474M of net new capital in Q4 2020, opening 22 new positions and adding to 12 existing holdings. Its largest new stake was BioAtla: 63,587 shares worth $108M.

By sector, the portfolio is most concentrated in Healthcare at 44% of assets, down from 94% a quarter earlier, followed by Consumer Staples and Real Estate.

On the sell side, the largest reduction was Inhibrx, Inc. Common Stock, an estimated $5.13M trimmed.

  • Soleus Capital Management's largest Q4 2020 buy was BioAtla: 63,587 shares worth $108M.
  • Soleus Capital Management added most to LYRA THERAPEUTICS INC in Q4 2020, an estimated $3.89M increase.
  • Soleus Capital Management's biggest Q4 2020 reduction was Inhibrx, Inc. Common Stock, cutting an estimated $5.13M.
  • Soleus Capital Management fully exited OraSure Technologies in Q4 2020, selling an estimated $7.61M.
  • Soleus Capital Management's ten largest holdings make up 81% of its $758M portfolio in Q4 2020.
  • Soleus Capital Management opened 22 new positions and closed 20 in Q4 2020.
  • Soleus Capital Management's portfolio value rose 302% quarter-over-quarter to $758M.

Based on Soleus Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.